An Open Label, Phase I Study to Evaluate the Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation Positive Cancer Patients
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Jul 2017
At a glance
- Drugs Vemurafenib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Roche
- 05 Jul 2017 Planned End Date changed from 1 Nov 2016 to 14 Jul 2017.
- 05 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Jan 2014 Planned End Date changed from 1 Jul 2019 to 1 Nov 2016 as reported by ClinicalTrials.gov record..